Simcere Pharmaceutical Group (HKSE:02096) Gross-Profit-to-Asset % : 41.16% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Simcere Pharmaceutical Group Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Simcere Pharmaceutical Group's annualized Gross Profit for the quarter that ended in Dec. 2023 was HK$5,300 Mil. Simcere Pharmaceutical Group's average Total Assets over the quarter that ended in Dec. 2023 was HK$12,876 Mil. Therefore, Simcere Pharmaceutical Group's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 41.16%.

Simcere Pharmaceutical Group Gross-Profit-to-Asset % Historical Data

The historical data trend for Simcere Pharmaceutical Group's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Simcere Pharmaceutical Group Gross-Profit-to-Asset % Chart

Simcere Pharmaceutical Group Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

62.67

41.73

37.77

45.57

45.58

Simcere Pharmaceutical Group Semi-Annual Data
	Dec17	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial							45.19	41.69	53.80	43.22	41.16

Competitive Comparison of Simcere Pharmaceutical Group's Gross-Profit-to-Asset %

For the Drug Manufacturers - Specialty & Generic subindustry, Simcere Pharmaceutical Group's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Simcere Pharmaceutical Group's Gross-Profit-to-Asset % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Simcere Pharmaceutical Group's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Simcere Pharmaceutical Group's Gross-Profit-to-Asset % falls into.

Simcere Pharmaceutical Group Gross-Profit-to-Asset % Calculation

Simcere Pharmaceutical Group's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	5451.561	/	( (12048.181	+	11871.512)	/ 2 )
	=	5451.561	/	11959.8465
	=	45.58 %

Simcere Pharmaceutical Group's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	5300.13	/	( (13879.674	+	11871.512)	/ 2 )
	=	5300.13	/	12875.593
	=	41.16 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Simcere Pharmaceutical Group Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Simcere Pharmaceutical Group's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Simcere Pharmaceutical Group (HKSE:02096) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Simcere Pharmaceutical Group Ltd (HKSE:02096) » Definitions » Gross-Profit-to-Asset %

Traded in Other Exchanges

S2P:Germany

Address

No. 699-18, Xuanwu Road, Xuanwu District, Jiangsu, Nanjing, CHN, 210042

Website

https://www.simcere.com

Simcere Pharmaceutical Group Ltd is engaged in the R&D, production and commercialization of pharmaceuticals focused on generic pharmaceuticals. It has a diversified product portfolio focused on therapeutic areas, including, oncology (including cell therapy), nervous system diseases, autoimmune diseases and antiinfection. The company's products include Endostar, Enweida, Iremod, Sanbexin and Others.

Executives

Wang Xi	2305 Beneficiary of a trust
Ren Jinsheng	2202 Interest of your spouse
Right Wealth Holdings Limited	2501 Other
Wang Xi	2501 Other
Simcere Investments Group Limited	2501 Other
Excel Investments Group Limited	2501 Other
Simcere Pharmaceutical Holding Limited	2501 Other
Simcere Holding Limited	2501 Other
Artking Global Limited	2501 Other
Ren Zhen	2501 Other
Ren Yong	2501 Other
Ren Weidong	2501 Other
Peng Suqin	2501 Other
P&h Holdings Group Ltd.	2501 Other
Li Shimeng	2501 Other

Simcere Pharmaceutical Group (HKSE:02096) Headlines

No Headlines